DMRTC2

Across TCGA pan-cancer cohorts, DMRTC2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DMRTC2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher DMRTC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DMRTC2 expression acts as an unfavorable survival marker.

OV, CESC, and LUAD are the cancer types where DMRTC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.007	0.844	<.001	48	view →
CESC	OS	Median	II,III,IV	0.091	0.830	<.001	42	view →
LUAD	DFS	Median	All	0.404	0.793	<.001	32	view →
LGG	DFS	Median	All	0.219	0.832	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.366	0.786	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DMRTC2–OV (OS)

Open the OV breakdown →